ClinicalTrials.gg
Active, not recruitingNCT05029050ALPHA2PREVENTUpdated Nov 19, 2026

Dexmedetomidine or Clonidine Infusion for Prevention of Delirium After Open Heart Surgery

A Phase 4 interventional study of Dexmedetomidine and Clonidine in Delirium, Cognitive Decline and Frailty, sponsored by Oslo University Hospital. Active, not recruiting at 5 sites in Norway. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Oslo University Hospital · Phase 4, Interventional, and Prevention

How we know

Updated Nov 19, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Planned enrollment
5th of 78
900 · median 98
Started
2022
with 6 others
Phase 4
35 of 78
5 open now
Primary completion
2026-07
later than 7 of 16 live
Registered
60th of 78
by date

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 5th largest by planned enrollment, is one of 7 that started in 2022, is one of 35 in phase 4, reaches primary completion later than 7 of the 16 other live ones, and was the 60th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.

Read the detailed description

Delirium is a major public health concern without therapeutic options. It is an acute disturbance of attention and cognition, precipitated by an acute somatic condition. Delirious patients are often subject to off-label treatment with psychotropic drugs that have dubious effects.

The intravenous alpha-2-adrenergic receptor agonist dexmedetomidine, attenuating sympathetic nervous system activity, shows promise as treatment for delirium, but its use is limited to intensive care units (ICU). Its long-term cognitive effects are unknown. Clonidine is a pharmacodynamically similar drug that can be given orally and has been used for decades as an antihypertensive agent, but is else sparsely studied.

ALPHA2PREVENT will be a three-armed randomised controlled trial to study 1) whether repurposing of clonidine can represent a novel treatment option for delirium, and 2) the possible effects of both dexmedetomidine and clonidine on long-term cognitive trajectories, motor activity patterns, patient rated outcome measures and biomarkers of neuronal injury.

03

Conditions studied

  • Delirium
  • Cognitive Decline
  • Frailty

Keywords

  • delirium
  • cognitive decline
  • frailty
  • heart surgery
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Participant must be ≥70 years old at the time of signing the .
  2. Participant must be accepted for cardiac surgery with cardiopulmonary bypass. The surgical procedures may constitute 1) coronary bypass grafting, 2) tricuspid, mitral, or aortic valve replacement or repair, 3) surgery on the ascending aorta, and 4) the combination any of these procedures.
  3. Participant must be capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Preoperative delirium
  2. Known to the active ingredient or components of the product
  3. Bradycardia due to sick-sinus-syndrome, 2nd or 3rd degree AV-block (if not treated with pacemaker) or any other reason causing HR \<50 bpm at time of inclusion
  4. Uncontrolled hypotension
  5. Ischemic stroke or transitory ischemic attack the last month or critical peripheral ischemia
  6. Acute coronary syndrome last 24 hours. Acute coronary syndrome is defined according to international guidelines
  7. \< 40%
  8. Severe renal impairment (estimated \<20ml/min) or expected requirement for renal replacement therapy
  9. Severe hepatic dysfunction (liver enzyme three times the together with a serum albumin concentration below the normal reference limit)
  10. Reduced peripheral autonomous activity (e.g. spinal cord injury)
  11. Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin
  12. Endocarditis or sepsis
  13. Pheochromocytoma
  14. Planned deep hypothermia and circulatory arrest
  15. Emergency surgery, defined as less than 24 hours from admission to surgery
  16. Previously included in this study
  17. Not speaking or reading Norwegian
  18. Any other condition as evaluated by the treating physician
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine (D)

    Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.

    Drug: Dexmedetomidine

  • Experimental
    Clonidine (C)

    Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.

    Drug: Clonidine

  • Placebo comparator
    Placebo (P)

    Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.

    Drug: Natriumchlorid

Interventions

  • Continous intravenous infusion

    Also known as: Dexdor, Precedex, N05C M18

  • Continous intravenous infusion

    Also known as: Catapresan, Catapressan, N02C X02

  • DrugNatriumchlorid

    Continous intravenous infusion NaCl

    Also known as: Saline, NaCl 9mg/ml

06

What researchers measure

Primary outcomes

  1. Postoperative delirium

    Cumulative incidence of postoperative delirium, as diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria

    Time frame: Up to 7 days

Secondary outcomes

  1. Incidence of coma

    Incidence of coma, as measured by Richmond Agitation Sedation Scale (-5 to +5)

    Time frame: Up to 7 days

  2. Incidence of death, coma or postoperative delirium

    Incidence of death, coma or postoperative delirium, as described above

    Time frame: Up to 7 days

  3. Number of delirium days postoperatively

    Number of delirium days postoperatively, as diagnosed according to DSM-5 criteria

    Time frame: Up to 7 days

  4. Delirium severity

    Delirium severity, as measured by Confusion Assessment Method for Intensive Care Units-7 (CAM-ICU)-7

    Time frame: Up to 7 days

  5. Motor activity patterns

    Motor activity patterns, assessed with body worn accelerometers

    Time frame: 6 months

  6. Change in cognitive function between inclusion and after 1 and 6 months

    Change in cognitive function between inclusion and after 1 and 6 months, as graded by Montreal Cognitive Assessment (MoCA), 10-words memory task from The Consortium Establish a Registry for Alzheimer's Disease (CERAD), digit span tests, Trail making tests (TMT) A and B, semantic and phonemic verbal fluency, and measured repeatedly preoperatively and 1 and 6 months after surgery

    Time frame: 6 months

  7. Change in patient rated health status between inclusion and after 1 and 6 months

    Change in patient rated health status between inclusion and after 1 and 6 months, as assessed by the EQ-5D-5L questionnaire preoperatively and 1 and 6 months postoperatively

    Time frame: 6 months

  8. Serum concentrations of NFL and p-tau181

    Comparison to inclusion of serum concentrations of neurofilament light (NFL) and p-tau181 1, 3 and 5 days postoperatively

    Time frame: 5 days postoperatively

  9. Estimate associations between frailty and the other endpoints

    Estimate associations between frailty and the other endpoints, as described above

    Time frame: 6 months

  10. Safety and tolerability

    Safety and tolerability as determined by the numbers of Adverse Events (AEs), serious AEs (SAEs) and suspected unexpected serious adverse reactions (SUSARs), and vital signs; blood pressure (BP), heart rate (HR), peripheral oxygen saturation (SpO2) postoperatively

    Time frame: 6 months

  11. Interaction between preoperative frailty and treatment on delirium and the other endpoints

    Interaction between preoperative frailty and treatment on delirium and the other endpoints, as described above

    Time frame: 6 months

  12. Change in frailty status between inclusion and after 1 and 6 months

    Change in frailty status between inclusion and after 1 and 6 months, as graded by the frailty index (FI) and essential frailty toolset (EFT) (section 8.1.3), and measured repeatedly preoperatively and 1 and 6 months after surgery

    Time frame: 6 months

  13. Comparison of change in frailty status between inclusion and after 1 and 6 months

    Comparison of change in frailty status between inclusion and after 1 and 6 months (as described above) between patients with or without postoperative delirium.

    Time frame: 6 months

Other outcomes

  1. Additional biomarkers

    Additional biomarkers of neural injury, inflammation or neurotransmission may be explored

    Time frame: 5 days postoperatively

07

Study locations

5 sites
08

References and documents

Publications

  • Neerland BE, Busund R, Haaverstad R, Helbostad JL, Landsverk SA, Martinaityte I, Norum HM, Raeder J, Selbaek G, Simpson MR, Skaar E, Skjaervold NK, Skovlund E, Slooter AJ, Svendsen OS, Tonnessen T, Wahba A, Zetterberg H, Wyller TB. Alpha-2-adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): protocol for a multicentre randomised controlled trial. BMJ Open. 2022 Jun 20;12(6):e057460. doi: 10.1136/bmjopen-2021-057460. PubMed 35725264 ↗

Individual participant data

Plan to share: Yes

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jul 2026, 54 months.

Of 40 non-industry phase 4 interventional studies under Delirium, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 62. This study's 54 months is above that.

Counting every sponsor, half of 40 studies reached it within 44 months; a quarter within 25 and three quarters within 62.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jul 2024 → Jul 2026 and completion Jan 2025 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2021
First posted
Aug 31, 2021
StartActual
Jan 17, 2022
Primary completionActual
Jul 31, 2026was Jul 2024
CompletionEst.
Jan 2027was Jan 2025
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 19, 2026
Primary completion
Jul 2024→Jul 31, 2026 (actual)
Nov 19, 2026
Study completion
Jan 2025→Jan 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 2024→Jul 31, 2026 (now actual)
    Study completion Jan 2025→Jan 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05029050
Responsible party
Bjørn Erik Neerland, MD (Medical doctor, postdoctoral researcher, Oslo University Hospital) — Principal investigator
First posted
Aug 31, 2021
Start date
Jan 17, 2022
Primary completion
Jul 31, 2026
Completion
Jan 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Bjørn Erik Neerland, PhD
principal investigator · Oslo University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Clonidine

Start the discussion